By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    healthy hobbies
    The Importance of Hobbies for Our Health
    September 15, 2024
    Whiplash
    Understanding Whiplash: A Guide For Healthcare Practitioners
    January 22, 2025
    research chemicals and health care
    Chemical Research Drive Medical Breakthroughs
    June 14, 2023
    Latest News
    7 Most Common Healthcare Accreditation Programs: Which Should You Use?
    August 20, 2025
    Hospital Pest Control and the Fight Against Superbugs
    August 20, 2025
    Hygiene Beyond The Clinic: Attention To Overlooked Non-Clinical Spaces
    August 13, 2025
    5 Steps to a Promising Career as a Healthcare Administrator
    August 3, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Hospitals and Providers Using NHIN (Nationwide Health Information Network)
    March 11, 2012
    Image
    Physicians With High Productivity And Satisfaction Scores Employ Strong Patient-Centered Communication Skills
    May 7, 2013
    My Solution to the Healthcare Crisis
    March 31, 2012
    Latest News
    How Social Security Disability Shapes Access to Care and Everyday Health
    August 22, 2025
    How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
    August 22, 2025
    How One Fall Can Lead to a Long Road of Medical Complications
    August 22, 2025
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Supreme Court Breaks Myriad Monopoly
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Supreme Court Breaks Myriad Monopoly
BusinessNewsPolicy & Law

Supreme Court Breaks Myriad Monopoly

Dan Munro
Dan Munro
Share
8 Min Read
SHARE

(Editor’s note: Dan Munro writes for Forbes.com under the heading: HealthCare Compass)

(Editor’s note: Dan Munro writes for Forbes.com under the heading: HealthCare Compass)

The pause was brief last Thursday morning as Dr. J. Craig Venter ended his keynote at the CALBIO event in San Diego. It was just long enough for someone to walk up to a floor microphone and ask the question that was absolutely in the air – if not on everyone’s mind. Basically, what did Dr. Venter think of the Supreme Court’s decision on the Myriad Genetics case – which was breaking news that very morning?

“I applaud the Supreme Court’s decision today … which was the right thing to do.” J. Craig Venter, Ph.D., Founder, Chairman and CEO of the J. Craig Venter Institute (JCVI)

More Read

Loss Of Health Insurance and Medications Cited as Potential Motive For Shootings
Delivering High Quality Healthcare: Measure, Improve, Measure Again
Shared Decision Making: Not Ready For Prime Time
HIPAA Compliance Breaches Higher Than Ever: What Are You Doing About It?
Patient Nonadherence: A Rational Reaction to Sub-Optimal Physician-Patient Communication

Mary-Claire King, the geneticist who actually discovered the BRCA-1 and BRCA-2 genes, was “delighted” and added this quote to an article in Slate.

“Genes had been patented before; the cystic fibrosis gene was patented. But I don’t think anyone – from the U.S. National Institutes of Health or anywhere else – anticipated the level of patent protection Myriad has engaged in.” Mary-Claire King – Geneticist and Professor at the University of Washington

I managed to catch up with Dr. David Agus by email who noted the landmark ruling would transform medicine into a new molecular era. 

“Effectively, the Supreme Court has democratized DNA. We all know the decision made sense on moral grounds, but this is a case where it’s so nice to see the judicial system agreeing.” Dr. David Agus – noted author and Professor of Medicine and Engineering at the University of Southern California

The consensus was generally bullish – except of course for Myriad’s stock price (NASDAQ: MYGN). During the breaking news cycle the stock climbed about $5 reaching a peak of almost $38 on Thursday. At Friday’s close, however, it was down to $27.59 – almost 20% down from Wednesday’s close of $33.92.

There were also a number of skeptics inside the biotech industry that seemed to think this landmark ruling was bad for the diagnostics industry generally. I didn’t get a chance to speak with many, but I did manage to connect with Dr. Sherri Bale of GeneRx. Her company plans to release a BRCA test to compete head-to-head with Myriad later this summer. Her view was clearly optimistic.

“We’ve waited a long time for this day, and now the playing field is leveled. We will deliver this test, as well as others, which until now we’ve been restricted from offering. We will now be able to compete on price as well as quality, customer service, and patient-friendly billing policies. Our alternative, called BRACfast, will be available August 1.”  Sherri J. Bale, PhD, FACMG, Managing Director, GeneDx and Sr. Vice President, BioReference Laboratories, Inc.

Other genetic testing companies were quick to brandish freshly minted web pages with billing codes and pricing. This chart is a representation of one online PDF available from Ambry Genetics (here):

                       

For a more precise legal interpretation I turned to patent attorney (and DLA Piper Partner) Stacy Taylor. She graciously provided her expert legal opinion as it applies to a broad range of constituents.

Plaintiffs and Patients:

 “This is really a pyrrhic victory for the ACLU. I spoke with an ACLU attorney shortly after the initial Myriad complaint was filed. He confirmed the principal intention of the suit was to enable laboratories to offer BRCA testing at substantially lower price points than Myriad and for use in second opinions. By itself, the Supreme Court ruling this week does not necessarily accomplish that end. While testing may be available a few months before Myriad’s patents would have expired anyway, the prices being discussed (still in the thousands) won’t be that much more affordable for patients if insurers don’t cover the test.” 

Insurers:

“So far, there doesn’t seem to have been any organized effort to challenge insurers with respect to any diagnostic assay coverage, including BRCA assays. However, once realization sets in that the Myriad decision really didn’t have much impact on assay access, insurers may well be the next target for litigation.

Researchers:

“For future patenting, Myriad merely serves as a roadmap for patent counsel to claim the synthetic DNA counterparts to genomic DNA and methods for its use. Those claims will be more difficult to obtain, but not because of the Myriad decision. Instead, the publication of data from sequencing of the human genome means that gene sequences will be known, so claims to them will be limited. Also, Myriad doesn’t affect claims to methods for using genetic sequences and related data. New diagnostic/prognostic tests will continue to be protectable (subject to limitations in the Mayo v. Prometheus decision). In short, the diagnostics industry is as viable – and fundable – now as it was yesterday.”

Supreme Court Impact:

“Many Court watchers have long felt that the Supreme Court isn’t competent to decide scientifically intensive issues. The Myriad decision doesn’t do anything to change that perception. To the contrary, Justice Scalia essentially admitted in his concurring opinion that he didn’t understand the science well enough to rule on it, though he was willing to accept the majority’s view that synthetic DNA is patent eligible. By itself, that extraordinary admission makes the Mryiad decision worth reading.”

Stacy Taylor – Patent Attorney and DLA Piper Partner (DLA Piper Bio here)

The debate around big research costs and profit incentives remains fairly unaltered – and perhaps unalterable. Nowhere was this more evident than this 4½ min interview clip (here) of Myriad Genetics Founder (and former CEO) Mark Skolnick by Joanna Rudnick for her documentary In The Family. In 2007 she asked the question directly:

Q: “You [Myriad] said this test will one day be 100’s of dollars. Why is it still $3,000? Why is it increasing?” Joanna Rudnick – film documentarian

A: “That’s a good question and I think there’s a point at which we have to start looking at decreasing the cost of the test.” Founder and Former Myriad Genetics CEO – Mark Skolnick

That was 6 years ago. Today the Myriad BRCA-1/2 test is more than $4,000. With the freshly minted Supreme Court ruling we may start to see the mechanics of free market competition bring that cost down – but we’re still a long way from the 100’s of dollars that Joanna Rudnick highlighted back in 2007. Dr. Venter applauded the Supreme Court for doing the right thing. Now it’s time for the biotech and insurance industries to follow that lead.

Original Post

TAGGED:pharmasupreme court
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025
engineer fitting prosthetic arm
How Social Security Disability Shapes Access to Care and Everyday Health
Health care
August 20, 2025
a woman explaining the document
How a DUI Lawyer Can Help When Your Future Health Feels Uncertain
Public Health
August 20, 2025

You Might also Like

Hospital-Website-Design-Healthcare-Marketing-Digital-Marketing
BusinessHospital Administration

Attracting the Attention of the Future Patient: 4 Elements to Consider When Designing Your Hospital’s Website

July 30, 2015
Medical EducationPublic Health

4 Kinds of Health Education for a More Healthy Society

June 20, 2016
affordable care act
Health ReformPolicy & Law

Can the “Government Shutdown” Shut Down ObamaCare?

September 25, 2013
hospital marketing questions
BusinesseHealth

5 Questions to Ask About Your Hospital Marketing Plan

May 9, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?